Aryan Pasricha

发表

Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial

Deepak L. Bhatt, Lawrence A Leiter, M. Lafreniere-Roula, 2022, Circulation.

The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease

A. Yan, K. Connelly, C. Mazer, 2023, Diabetes, obesity & metabolism.

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.

B. Mulsant, D. Blumberger, J. Rosenblat, 2023, Journal of psychoactive drugs.